Evoke Pharma, Inc (EVOK): Price to Sales

Brandmark of Evoke Pharma, Inc (EVOK)

Evoke Pharma, Inc. (EVOK) focuses on marketing, having outsourced the production of nasal products to external contractors. The price-to-sales ratio visualizes this dependence on CMOs, with 1.30 serving as the current parameter value. The company optimizes expenses by delegating international distribution to logistics operators. Growth relies on the promotion of the Gimoti spray, the expansion of insurance reimbursements, and the strengthening of its own sales force.

P/S Multiple: Evoke Pharma, Inc (EVOK) for 07/04/2022 - 12/27/2025

Metric breakdowns and analytics for Evoke Pharma, Inc (EVOK)

- current price and projected stock value:
Price Chart Evoke Pharma Inc.|EVOK - Price Target Chart
- stock exchange capitalization data:
Market Value Evoke Pharma|EVOK - Total Company Value
- shareholders' equity book value data:
Book Value per Share Evoke Pharma|EVOK - Book Capitalization|Market-to-Book Ratio evokepharma.com|EVOK - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Evoke Pharma, Inc.|EVOK - Long-Term Debt to Equity|Current Liabilities to Equity Evoke Pharma, Inc.|EVOK - Company Aggregate Debts|Debt to Net Assets Ratio Evoke Pharma Inc|EVOK - Company Long-Term Debts|Company Short-Term Debts Evoke Pharma|Intermediate Coverage Ratio evokepharma.com
- company profitability and valuation multiples indicators:
EVOK - Company Net Income|Future Profit Evoke Pharma, Inc.|EVOK - P/E Multiple|Forward P/E Multiple Evoke Pharma, Inc.|EVOK - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Evoke Pharma Inc|EVOK - Operating profit EBITDA|Net earnings per share for the last four quarters Evoke Pharma|EVOK - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months evokepharma.com|EVOK - Earnings growth in current year|Expected earnings per share growth for next year Evoke Pharma, Inc.
- issuer revenue and sales details:
EVOK - Company Sales|Company Future Sales Evoke Pharma|EVOK - P/S Multiple|Market Cap to Future Revenue Ratio Evoke Pharma, Inc.|EVOK - Revenue Growth YoY (Last 12 Months)
General company analysis:Evoke Pharma, EVOK
Finished products of Evoke Pharma Inc.

The P/S multiple compares market capitalization to annual sales volume, determining the value of one dollar of revenue in the eyes of investors. For Evoke Pharma, Inc. (EVOK), which maintains a strong scientific staff of biochemists while expanding its commercial department, current P/S dynamics serve as an indicator of monetization efficiency for its developments, allowing a distinction between fundamental growth and speculative asset inflation.

Competing companies

PHAT (Phathom Pharmaceuticals, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Terns Pharmaceuticals Inc TERN|Ironwood Pharmaceuticals (IRWD) - Price to Sales|Curanex Pharmaceuticals Inc - P/S Multiple|IMRN - P/S Multiple|Entero (ENTO) - Price-to-Revenue Ratio|RDHL - Price-to-Revenue Coefficient|PALI (Palisade Bio Inc.) - P/S Multiple|JAGX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BIOR (Progenity)|Market Cap to Revenue Morphic MORF